Charles Schwab Investment Management Inc. Has $19.13 Million Stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Charles Schwab Investment Management Inc. grew its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 1.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,017,720 shares of the biotechnology company’s stock after purchasing an additional 10,785 shares during the period. Charles Schwab Investment Management Inc. owned about 0.81% of Arrowhead Pharmaceuticals worth $19,133,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. State Street Corp grew its position in Arrowhead Pharmaceuticals by 8.8% in the 3rd quarter. State Street Corp now owns 6,354,331 shares of the biotechnology company’s stock worth $123,083,000 after purchasing an additional 516,569 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Arrowhead Pharmaceuticals by 0.9% during the 3rd quarter. Geode Capital Management LLC now owns 2,964,119 shares of the biotechnology company’s stock valued at $57,426,000 after acquiring an additional 26,171 shares in the last quarter. abrdn plc boosted its position in shares of Arrowhead Pharmaceuticals by 12.2% during the 4th quarter. abrdn plc now owns 450,075 shares of the biotechnology company’s stock valued at $8,461,000 after acquiring an additional 48,929 shares in the last quarter. Rhumbline Advisers boosted its position in shares of Arrowhead Pharmaceuticals by 2.1% during the 4th quarter. Rhumbline Advisers now owns 380,344 shares of the biotechnology company’s stock valued at $7,150,000 after acquiring an additional 7,912 shares in the last quarter. Finally, Fisher Asset Management LLC boosted its position in shares of Arrowhead Pharmaceuticals by 16.9% during the 4th quarter. Fisher Asset Management LLC now owns 142,939 shares of the biotechnology company’s stock valued at $2,687,000 after acquiring an additional 20,679 shares in the last quarter. 62.61% of the stock is currently owned by institutional investors and hedge funds.

Arrowhead Pharmaceuticals Trading Up 2.5 %

Shares of ARWR stock opened at $15.47 on Thursday. Arrowhead Pharmaceuticals, Inc. has a 12-month low of $14.23 and a 12-month high of $30.41. The company has a market capitalization of $2.12 billion, a P/E ratio of -2.99 and a beta of 0.92. The firm has a 50-day moving average price of $18.75 and a 200 day moving average price of $20.01. The company has a quick ratio of 6.09, a current ratio of 6.09 and a debt-to-equity ratio of 7.27.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its earnings results on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.97). Research analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on ARWR shares. StockNews.com upgraded shares of Arrowhead Pharmaceuticals to a “sell” rating in a research report on Friday, December 20th. B. Riley reiterated a “buy” rating and set a $38.00 target price (down from $51.00) on shares of Arrowhead Pharmaceuticals in a research report on Friday, February 14th. Piper Sandler decreased their target price on shares of Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 27th. Royal Bank of Canada reiterated an “outperform” rating and set a $42.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. Finally, Sanford C. Bernstein decreased their target price on shares of Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating on the stock in a research report on Friday, November 29th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $41.44.

Insiders Place Their Bets

In related news, insider James C. Hamilton sold 32,729 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $19.82, for a total transaction of $648,688.78. Following the completion of the sale, the insider now directly owns 272,122 shares of the company’s stock, valued at $5,393,458.04. The trade was a 10.74 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Christopher Richard Anzalone sold 51,425 shares of the business’s stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $15.07, for a total transaction of $774,974.75. Following the sale, the chief executive officer now directly owns 4,062,377 shares of the company’s stock, valued at approximately $61,220,021.39. This trade represents a 1.25 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 301,730 shares of company stock valued at $5,352,844. Insiders own 4.30% of the company’s stock.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.